Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) Stock Competitors & Peer Comparison
See (OCUL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OCUL | $10.98 | +22.82% | 2.4B | -7.73 | -$1.42 | N/A |
| VRTX | $486.03 | -2.17% | 123.5B | 31.77 | $15.30 | N/A |
| REGN | $790.81 | +1.17% | 82.2B | 19.05 | $41.51 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $756.76 | -1.32% | 46.8B | 32.38 | $23.38 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $325.07 | -2.36% | 43.1B | 139.45 | $2.33 | N/A |
| INSM | $146.32 | -2.02% | 31.2B | -23.60 | -$6.20 | N/A |
| BNTX | $107.48 | -2.49% | 25.8B | -38.11 | -$2.82 | N/A |
| UTHR | $513.82 | +1.97% | 23.2B | 19.46 | $26.40 | N/A |
Stock Comparison
OCUL vs VRTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, VRTX has a market cap of 123.5B. Regarding current trading prices, OCUL is priced at $10.98, while VRTX trades at $486.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas VRTX's P/E ratio is 31.77. In terms of profitability, OCUL's ROE is -0.72%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, OCUL is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check VRTX's competition here
OCUL vs REGN Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, REGN has a market cap of 82.2B. Regarding current trading prices, OCUL is priced at $10.98, while REGN trades at $790.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas REGN's P/E ratio is 19.05. In terms of profitability, OCUL's ROE is -0.72%, compared to REGN's ROE of +0.15%. Regarding short-term risk, OCUL is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check REGN's competition here
OCUL vs VRNA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, OCUL is priced at $10.98, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas VRNA's P/E ratio is -102.80. In terms of profitability, OCUL's ROE is -0.72%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, OCUL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check VRNA's competition here
OCUL vs ARGX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ARGX has a market cap of 46.8B. Regarding current trading prices, OCUL is priced at $10.98, while ARGX trades at $756.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ARGX's P/E ratio is 32.38. In terms of profitability, OCUL's ROE is -0.72%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, OCUL is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ARGX's competition here
OCUL vs SGEN Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, OCUL is priced at $10.98, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas SGEN's P/E ratio is -57.19. In terms of profitability, OCUL's ROE is -0.72%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, OCUL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SGEN's competition here
OCUL vs ALNY Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ALNY has a market cap of 43.1B. Regarding current trading prices, OCUL is priced at $10.98, while ALNY trades at $325.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ALNY's P/E ratio is 139.45. In terms of profitability, OCUL's ROE is -0.72%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, OCUL is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ALNY's competition here
OCUL vs INSM Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, INSM has a market cap of 31.2B. Regarding current trading prices, OCUL is priced at $10.98, while INSM trades at $146.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas INSM's P/E ratio is -23.60. In terms of profitability, OCUL's ROE is -0.72%, compared to INSM's ROE of -1.68%. Regarding short-term risk, OCUL is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check INSM's competition here
OCUL vs BNTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BNTX has a market cap of 25.8B. Regarding current trading prices, OCUL is priced at $10.98, while BNTX trades at $107.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BNTX's P/E ratio is -38.11. In terms of profitability, OCUL's ROE is -0.72%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, OCUL is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BNTX's competition here
OCUL vs UTHR Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, UTHR has a market cap of 23.2B. Regarding current trading prices, OCUL is priced at $10.98, while UTHR trades at $513.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas UTHR's P/E ratio is 19.46. In terms of profitability, OCUL's ROE is -0.72%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, OCUL is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check UTHR's competition here
OCUL vs MRNA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MRNA has a market cap of 20.6B. Regarding current trading prices, OCUL is priced at $10.98, while MRNA trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MRNA's P/E ratio is -7.28. In terms of profitability, OCUL's ROE is -0.72%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, OCUL is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MRNA's competition here
OCUL vs RPRX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, OCUL is priced at $10.98, while RPRX trades at $47.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas RPRX's P/E ratio is 26.67. In terms of profitability, OCUL's ROE is -0.72%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, OCUL is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RPRX's competition here
OCUL vs BGNE Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, OCUL is priced at $10.98, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BGNE's P/E ratio is -22.55. In terms of profitability, OCUL's ROE is -0.72%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, OCUL is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BGNE's competition here
OCUL vs ROIV Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ROIV has a market cap of 20.1B. Regarding current trading prices, OCUL is priced at $10.98, while ROIV trades at $28.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ROIV's P/E ratio is -24.02. In terms of profitability, OCUL's ROE is -0.72%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, OCUL is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ROIV's competition here
OCUL vs INCY Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, INCY has a market cap of 19.9B. Regarding current trading prices, OCUL is priced at $10.98, while INCY trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas INCY's P/E ratio is 15.61. In terms of profitability, OCUL's ROE is -0.72%, compared to INCY's ROE of +0.29%. Regarding short-term risk, OCUL is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check INCY's competition here
OCUL vs RVMD Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, RVMD has a market cap of 19.6B. Regarding current trading prices, OCUL is priced at $10.98, while RVMD trades at $101.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas RVMD's P/E ratio is -19.58. In terms of profitability, OCUL's ROE is -0.72%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, OCUL is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RVMD's competition here
OCUL vs DNA-WT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, OCUL is priced at $10.98, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, OCUL's ROE is -0.72%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, OCUL is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check DNA-WT's competition here
OCUL vs GMAB Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, GMAB has a market cap of 18.3B. Regarding current trading prices, OCUL is priced at $10.98, while GMAB trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas GMAB's P/E ratio is 19.25. In terms of profitability, OCUL's ROE is -0.72%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, OCUL is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check GMAB's competition here
OCUL vs ASND Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ASND has a market cap of 14.9B. Regarding current trading prices, OCUL is priced at $10.98, while ASND trades at $242.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ASND's P/E ratio is -54.52. In terms of profitability, OCUL's ROE is -0.72%, compared to ASND's ROE of +1.28%. Regarding short-term risk, OCUL is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ASND's competition here
OCUL vs IONS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, IONS has a market cap of 13.3B. Regarding current trading prices, OCUL is priced at $10.98, while IONS trades at $81.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas IONS's P/E ratio is -50.91. In terms of profitability, OCUL's ROE is -0.72%, compared to IONS's ROE of -0.69%. Regarding short-term risk, OCUL is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IONS's competition here
OCUL vs BBIO Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, OCUL is priced at $10.98, while BBIO trades at $65.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BBIO's P/E ratio is -17.33. In terms of profitability, OCUL's ROE is -0.72%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, OCUL is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BBIO's competition here
OCUL vs KRTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, OCUL is priced at $10.98, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas KRTX's P/E ratio is -28.09. In terms of profitability, OCUL's ROE is -0.72%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, OCUL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check KRTX's competition here
OCUL vs SMMT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, SMMT has a market cap of 12.1B. Regarding current trading prices, OCUL is priced at $10.98, while SMMT trades at $16.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas SMMT's P/E ratio is -12.95. In terms of profitability, OCUL's ROE is -0.72%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, OCUL is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SMMT's competition here
OCUL vs JAZZ Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, JAZZ has a market cap of 11.7B. Regarding current trading prices, OCUL is priced at $10.98, while JAZZ trades at $190.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas JAZZ's P/E ratio is -32.67. In terms of profitability, OCUL's ROE is -0.72%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, OCUL is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check JAZZ's competition here
OCUL vs BMRN Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, OCUL is priced at $10.98, while BMRN trades at $59.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BMRN's P/E ratio is 22.21. In terms of profitability, OCUL's ROE is -0.72%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, OCUL is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BMRN's competition here
OCUL vs EXEL Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, EXEL has a market cap of 11B. Regarding current trading prices, OCUL is priced at $10.98, while EXEL trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas EXEL's P/E ratio is 14.76. In terms of profitability, OCUL's ROE is -0.72%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, OCUL is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check EXEL's competition here
OCUL vs IBRX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, IBRX has a market cap of 10.3B. Regarding current trading prices, OCUL is priced at $10.98, while IBRX trades at $10.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas IBRX's P/E ratio is -25.46. In terms of profitability, OCUL's ROE is -0.72%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, OCUL is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IBRX's competition here
OCUL vs MDGL Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, OCUL is priced at $10.98, while MDGL trades at $435.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MDGL's P/E ratio is -33.90. In terms of profitability, OCUL's ROE is -0.72%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, OCUL is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MDGL's competition here
OCUL vs RXDX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, OCUL is priced at $10.98, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas RXDX's P/E ratio is -56.47. In terms of profitability, OCUL's ROE is -0.72%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, OCUL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RXDX's competition here
OCUL vs TECH Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, TECH has a market cap of 9B. Regarding current trading prices, OCUL is priced at $10.98, while TECH trades at $57.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas TECH's P/E ratio is 109.09. In terms of profitability, OCUL's ROE is -0.72%, compared to TECH's ROE of +0.04%. Regarding short-term risk, OCUL is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check TECH's competition here
OCUL vs ARWR Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, OCUL is priced at $10.98, while ARWR trades at $64.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ARWR's P/E ratio is 40.21. In terms of profitability, OCUL's ROE is -0.72%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, OCUL is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ARWR's competition here
OCUL vs PCVX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, OCUL is priced at $10.98, while PCVX trades at $61.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas PCVX's P/E ratio is -12.78. In terms of profitability, OCUL's ROE is -0.72%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, OCUL is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check PCVX's competition here
OCUL vs IMGN Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, OCUL is priced at $10.98, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas IMGN's P/E ratio is -111.55. In terms of profitability, OCUL's ROE is -0.72%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, OCUL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IMGN's competition here
OCUL vs AXSM Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, AXSM has a market cap of 8.5B. Regarding current trading prices, OCUL is priced at $10.98, while AXSM trades at $166.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas AXSM's P/E ratio is -45.05. In terms of profitability, OCUL's ROE is -0.72%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, OCUL is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check AXSM's competition here
OCUL vs BPMC Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, OCUL is priced at $10.98, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BPMC's P/E ratio is -51.58. In terms of profitability, OCUL's ROE is -0.72%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, OCUL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BPMC's competition here
OCUL vs HALO Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, OCUL is priced at $10.98, while HALO trades at $69.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas HALO's P/E ratio is 27.29. In terms of profitability, OCUL's ROE is -0.72%, compared to HALO's ROE of +0.93%. Regarding short-term risk, OCUL is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check HALO's competition here
OCUL vs CERE Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, OCUL is priced at $10.98, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CERE's P/E ratio is -16.47. In terms of profitability, OCUL's ROE is -0.72%, compared to CERE's ROE of -0.72%. Regarding short-term risk, OCUL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CERE's competition here
OCUL vs KRYS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, OCUL is priced at $10.98, while KRYS trades at $258.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas KRYS's P/E ratio is 37.84. In terms of profitability, OCUL's ROE is -0.72%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, OCUL is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check KRYS's competition here
OCUL vs CYTK Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, OCUL is priced at $10.98, while CYTK trades at $61.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CYTK's P/E ratio is -9.75. In terms of profitability, OCUL's ROE is -0.72%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, OCUL is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CYTK's competition here
OCUL vs MTSR Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, OCUL is priced at $10.98, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MTSR's P/E ratio is -23.58. In terms of profitability, OCUL's ROE is -0.72%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, OCUL is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MTSR's competition here
OCUL vs ABVX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ABVX has a market cap of 7.4B. Regarding current trading prices, OCUL is priced at $10.98, while ABVX trades at $113.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ABVX's P/E ratio is -21.55. In terms of profitability, OCUL's ROE is -0.72%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, OCUL is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ABVX's competition here
OCUL vs NUVL Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, NUVL has a market cap of 7.4B. Regarding current trading prices, OCUL is priced at $10.98, while NUVL trades at $101.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas NUVL's P/E ratio is -19.00. In terms of profitability, OCUL's ROE is -0.72%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, OCUL is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check NUVL's competition here
OCUL vs KYMR Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, KYMR has a market cap of 7.2B. Regarding current trading prices, OCUL is priced at $10.98, while KYMR trades at $90.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas KYMR's P/E ratio is -25.03. In terms of profitability, OCUL's ROE is -0.72%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, OCUL is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check KYMR's competition here
OCUL vs PRAX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, OCUL is priced at $10.98, while PRAX trades at $330.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas PRAX's P/E ratio is -25.51. In terms of profitability, OCUL's ROE is -0.72%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, OCUL is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check PRAX's competition here
OCUL vs MRUS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, OCUL is priced at $10.98, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MRUS's P/E ratio is -17.05. In terms of profitability, OCUL's ROE is -0.72%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, OCUL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MRUS's competition here
OCUL vs ACLX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ACLX has a market cap of 6.6B. Regarding current trading prices, OCUL is priced at $10.98, while ACLX trades at $114.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ACLX's P/E ratio is -29.02. In terms of profitability, OCUL's ROE is -0.72%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, OCUL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ACLX's competition here
OCUL vs RETA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, OCUL is priced at $10.98, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas RETA's P/E ratio is -66.29. In terms of profitability, OCUL's ROE is -0.72%, compared to RETA's ROE of +0.47%. Regarding short-term risk, OCUL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RETA's competition here
OCUL vs RYTM Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, OCUL is priced at $10.98, while RYTM trades at $94.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas RYTM's P/E ratio is -30.63. In terms of profitability, OCUL's ROE is -0.72%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, OCUL is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RYTM's competition here
OCUL vs COGT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, COGT has a market cap of 6.3B. Regarding current trading prices, OCUL is priced at $10.98, while COGT trades at $38.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas COGT's P/E ratio is -18.00. In terms of profitability, OCUL's ROE is -0.72%, compared to COGT's ROE of -1.00%. Regarding short-term risk, OCUL is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check COGT's competition here
OCUL vs BLTE Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, OCUL is priced at $10.98, while BLTE trades at $177.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BLTE's P/E ratio is -92.49. In terms of profitability, OCUL's ROE is -0.72%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, OCUL is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BLTE's competition here
OCUL vs PTGX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, PTGX has a market cap of 5.9B. Regarding current trading prices, OCUL is priced at $10.98, while PTGX trades at $94.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas PTGX's P/E ratio is 142.79. In terms of profitability, OCUL's ROE is -0.72%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, OCUL is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check PTGX's competition here
OCUL vs CRSP Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, OCUL is priced at $10.98, while CRSP trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CRSP's P/E ratio is -9.39. In terms of profitability, OCUL's ROE is -0.72%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, OCUL is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CRSP's competition here
OCUL vs CAI Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CAI has a market cap of 5.8B. Regarding current trading prices, OCUL is priced at $10.98, while CAI trades at $20.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CAI's P/E ratio is -5.87. In terms of profitability, OCUL's ROE is -0.72%, compared to CAI's ROE of +1.97%. Regarding short-term risk, OCUL is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CAI's competition here
OCUL vs IMVT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, OCUL is priced at $10.98, while IMVT trades at $27.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas IMVT's P/E ratio is -10.39. In terms of profitability, OCUL's ROE is -0.72%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, OCUL is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IMVT's competition here
OCUL vs CDTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, OCUL is priced at $10.98, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CDTX's P/E ratio is -19.77. In terms of profitability, OCUL's ROE is -0.72%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, OCUL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CDTX's competition here
OCUL vs ABCM Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, OCUL is priced at $10.98, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, OCUL's ROE is -0.72%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, OCUL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ABCM's competition here
OCUL vs ISEE Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, OCUL is priced at $10.98, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ISEE's P/E ratio is -22.44. In terms of profitability, OCUL's ROE is -0.72%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, OCUL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ISEE's competition here
OCUL vs PTCT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, OCUL is priced at $10.98, while PTCT trades at $66.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas PTCT's P/E ratio is 7.72. In terms of profitability, OCUL's ROE is -0.72%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, OCUL is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check PTCT's competition here
OCUL vs FBIOX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, OCUL is priced at $10.98, while FBIOX trades at $25.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas FBIOX's P/E ratio is N/A. In terms of profitability, OCUL's ROE is -0.72%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, OCUL is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check FBIOX's competition here
OCUL vs CELC Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CELC has a market cap of 5B. Regarding current trading prices, OCUL is priced at $10.98, while CELC trades at $108.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CELC's P/E ratio is -29.44. In terms of profitability, OCUL's ROE is -0.72%, compared to CELC's ROE of -1.79%. Regarding short-term risk, OCUL is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CELC's competition here
OCUL vs ALKS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, OCUL is priced at $10.98, while ALKS trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ALKS's P/E ratio is 15.05. In terms of profitability, OCUL's ROE is -0.72%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, OCUL is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ALKS's competition here
OCUL vs TGTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, OCUL is priced at $10.98, while TGTX trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas TGTX's P/E ratio is 10.61. In terms of profitability, OCUL's ROE is -0.72%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, OCUL is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check TGTX's competition here
OCUL vs CGON Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CGON has a market cap of 4.7B. Regarding current trading prices, OCUL is priced at $10.98, while CGON trades at $57.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CGON's P/E ratio is -28.18. In terms of profitability, OCUL's ROE is -0.72%, compared to CGON's ROE of -0.23%. Regarding short-term risk, OCUL is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CGON's competition here
OCUL vs MIRM Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, OCUL is priced at $10.98, while MIRM trades at $90.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MIRM's P/E ratio is -107.25. In terms of profitability, OCUL's ROE is -0.72%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, OCUL is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MIRM's competition here
OCUL vs FOLD Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $10.98, while FOLD trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas FOLD's P/E ratio is -359.00. In terms of profitability, OCUL's ROE is -0.72%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, OCUL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check FOLD's competition here
OCUL vs AKRO Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $10.98, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas AKRO's P/E ratio is -14.57. In terms of profitability, OCUL's ROE is -0.72%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, OCUL is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check AKRO's competition here
OCUL vs ERAS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ERAS has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $10.98, while ERAS trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ERAS's P/E ratio is -33.79. In terms of profitability, OCUL's ROE is -0.72%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, OCUL is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ERAS's competition here
OCUL vs ALPN Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $10.98, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ALPN's P/E ratio is -101.52. In terms of profitability, OCUL's ROE is -0.72%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, OCUL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ALPN's competition here
OCUL vs SRRK Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, SRRK has a market cap of 4.4B. Regarding current trading prices, OCUL is priced at $10.98, while SRRK trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas SRRK's P/E ratio is -13.80. In terms of profitability, OCUL's ROE is -0.72%, compared to SRRK's ROE of -1.22%. Regarding short-term risk, OCUL is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SRRK's competition here
OCUL vs OPT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, OCUL is priced at $10.98, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas OPT's P/E ratio is -1.52. In terms of profitability, OCUL's ROE is -0.72%, compared to OPT's ROE of +0.88%. Regarding short-term risk, OCUL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check OPT's competition here
OCUL vs CRNX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CRNX has a market cap of 4.2B. Regarding current trading prices, OCUL is priced at $10.98, while CRNX trades at $40.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CRNX's P/E ratio is -8.98. In terms of profitability, OCUL's ROE is -0.72%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, OCUL is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CRNX's competition here
OCUL vs MRTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, OCUL is priced at $10.98, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MRTX's P/E ratio is -4.82. In terms of profitability, OCUL's ROE is -0.72%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, OCUL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MRTX's competition here
OCUL vs LGND Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, OCUL is priced at $10.98, while LGND trades at $202.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas LGND's P/E ratio is 88.84. In terms of profitability, OCUL's ROE is -0.72%, compared to LGND's ROE of +0.14%. Regarding short-term risk, OCUL is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check LGND's competition here
OCUL vs ADMA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ADMA has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $10.98, while ADMA trades at $16.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ADMA's P/E ratio is 19.28. In terms of profitability, OCUL's ROE is -0.72%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, OCUL is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ADMA's competition here
OCUL vs APGE Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, APGE has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $10.98, while APGE trades at $70.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas APGE's P/E ratio is -16.17. In terms of profitability, OCUL's ROE is -0.72%, compared to APGE's ROE of -0.39%. Regarding short-term risk, OCUL is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check APGE's competition here
OCUL vs ACAD Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $10.98, while ACAD trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ACAD's P/E ratio is 14.72. In terms of profitability, OCUL's ROE is -0.72%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, OCUL is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ACAD's competition here
OCUL vs VKTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $10.98, while VKTX trades at $33.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas VKTX's P/E ratio is -10.45. In terms of profitability, OCUL's ROE is -0.72%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, OCUL is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check VKTX's competition here
OCUL vs CORT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CORT has a market cap of 3.8B. Regarding current trading prices, OCUL is priced at $10.98, while CORT trades at $35.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CORT's P/E ratio is 43.87. In terms of profitability, OCUL's ROE is -0.72%, compared to CORT's ROE of +0.15%. Regarding short-term risk, OCUL is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CORT's competition here
OCUL vs TERN Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, TERN has a market cap of 3.8B. Regarding current trading prices, OCUL is priced at $10.98, while TERN trades at $42.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas TERN's P/E ratio is -41.21. In terms of profitability, OCUL's ROE is -0.72%, compared to TERN's ROE of -0.30%. Regarding short-term risk, OCUL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check TERN's competition here
OCUL vs NAMS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, OCUL is priced at $10.98, while NAMS trades at $32.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas NAMS's P/E ratio is -19.09. In terms of profitability, OCUL's ROE is -0.72%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, OCUL is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check NAMS's competition here
OCUL vs RYZB Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, OCUL is priced at $10.98, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas RYZB's P/E ratio is -57.86. In terms of profitability, OCUL's ROE is -0.72%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, OCUL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RYZB's competition here
OCUL vs CBAY Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, OCUL is priced at $10.98, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CBAY's P/E ratio is -32.81. In terms of profitability, OCUL's ROE is -0.72%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, OCUL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CBAY's competition here
OCUL vs GPCR Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, GPCR has a market cap of 3.6B. Regarding current trading prices, OCUL is priced at $10.98, while GPCR trades at $62.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas GPCR's P/E ratio is -17.19. In terms of profitability, OCUL's ROE is -0.72%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, OCUL is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check GPCR's competition here
OCUL vs CNTA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, OCUL is priced at $10.98, while CNTA trades at $26.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CNTA's P/E ratio is -14.03. In terms of profitability, OCUL's ROE is -0.72%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, OCUL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CNTA's competition here
OCUL vs SWTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, OCUL is priced at $10.98, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas SWTX's P/E ratio is -13.78. In terms of profitability, OCUL's ROE is -0.72%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, OCUL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SWTX's competition here
OCUL vs KNSA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, KNSA has a market cap of 3.4B. Regarding current trading prices, OCUL is priced at $10.98, while KNSA trades at $46.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas KNSA's P/E ratio is 102.22. In terms of profitability, OCUL's ROE is -0.72%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, OCUL is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check KNSA's competition here
OCUL vs TARS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, TARS has a market cap of 3.3B. Regarding current trading prices, OCUL is priced at $10.98, while TARS trades at $77.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas TARS's P/E ratio is -48.70. In terms of profitability, OCUL's ROE is -0.72%, compared to TARS's ROE of -0.20%. Regarding short-term risk, OCUL is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check TARS's competition here
OCUL vs XENE Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, XENE has a market cap of 3.3B. Regarding current trading prices, OCUL is priced at $10.98, while XENE trades at $42.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas XENE's P/E ratio is -10.94. In terms of profitability, OCUL's ROE is -0.72%, compared to XENE's ROE of -0.56%. Regarding short-term risk, OCUL is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check XENE's competition here
OCUL vs DNLI Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, OCUL is priced at $10.98, while DNLI trades at $21.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas DNLI's P/E ratio is -7.19. In terms of profitability, OCUL's ROE is -0.72%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, OCUL is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check DNLI's competition here
OCUL vs EWTX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, EWTX has a market cap of 3.1B. Regarding current trading prices, OCUL is priced at $10.98, while EWTX trades at $29.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas EWTX's P/E ratio is -18.92. In terms of profitability, OCUL's ROE is -0.72%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, OCUL is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check EWTX's competition here
OCUL vs ALMS Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, OCUL is priced at $10.98, while ALMS trades at $29.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ALMS's P/E ratio is -13.82. In terms of profitability, OCUL's ROE is -0.72%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, OCUL is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ALMS's competition here
OCUL vs ARQT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, OCUL is priced at $10.98, while ARQT trades at $24.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas ARQT's P/E ratio is -72.82. In terms of profitability, OCUL's ROE is -0.72%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, OCUL is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ARQT's competition here
OCUL vs CPRX Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $10.98, while CPRX trades at $23.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas CPRX's P/E ratio is 13.96. In terms of profitability, OCUL's ROE is -0.72%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, OCUL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CPRX's competition here
OCUL vs BEAM Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, BEAM has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $10.98, while BEAM trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas BEAM's P/E ratio is -6.51. In terms of profitability, OCUL's ROE is -0.72%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, OCUL is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BEAM's competition here
OCUL vs IDYA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $10.98, while IDYA trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas IDYA's P/E ratio is -25.81. In terms of profitability, OCUL's ROE is -0.72%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, OCUL is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IDYA's competition here
OCUL vs MORF Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $10.98, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MORF's P/E ratio is -14.88. In terms of profitability, OCUL's ROE is -0.72%, compared to MORF's ROE of -0.29%. Regarding short-term risk, OCUL is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MORF's competition here
OCUL vs MOR Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $10.98, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas MOR's P/E ratio is -12.64. In terms of profitability, OCUL's ROE is -0.72%, compared to MOR's ROE of -1.84%. Regarding short-term risk, OCUL is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MOR's competition here
OCUL vs VCYT Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, VCYT has a market cap of 2.8B. Regarding current trading prices, OCUL is priced at $10.98, while VCYT trades at $36.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas VCYT's P/E ratio is 94.76. In terms of profitability, OCUL's ROE is -0.72%, compared to VCYT's ROE of +0.05%. Regarding short-term risk, OCUL is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check VCYT's competition here
OCUL vs VERA Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, VERA has a market cap of 2.8B. Regarding current trading prices, OCUL is priced at $10.98, while VERA trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas VERA's P/E ratio is -10.13. In terms of profitability, OCUL's ROE is -0.72%, compared to VERA's ROE of -0.60%. Regarding short-term risk, OCUL is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check VERA's competition here
OCUL vs NAMSW Comparison March 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 2.4B. In comparison, NAMSW has a market cap of 2.8B. Regarding current trading prices, OCUL is priced at $10.98, while NAMSW trades at $24.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -7.73, whereas NAMSW's P/E ratio is N/A. In terms of profitability, OCUL's ROE is -0.72%, compared to NAMSW's ROE of -0.27%. Regarding short-term risk, OCUL is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check NAMSW's competition here